Canopy Growth GAAP EPS of -C$0.01 beats by C$0.17, revenue of C$66.68M misses by C$5.14M

Canada adult-use revenue up 30% in Q2 FY2026 and 37% year-to-date, reflecting the benefits of our focused commercial strategy and more disciplined execution

Canada medical revenue up 17% in Q2 FY2026 and 15% year-to-date, marking another standout quarter for growth

C$298M cash and cash equivalents, which exceeds debt balances by C$70M at September 30, 2025; as a result, conditions that previously raised substantial doubt concerning the company’s ability to continue as a going concern have been resolved.